The DOI matches its Crossref record; 318 of the 318 references it cites were found in a registry or an index.
Hypoxia-targeted drug delivery
Open accessAbstract
Hypoxia is a state of low oxygen tension found in numerous solid tumours.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–318 of 318
Diflavin Oxidoreductases Activate the Bioreductive Prodrug PR-104A under Hypoxia
Guise, C. P., Abbattista, M. R., Tipparaju, S. R., Lambie, N., Su, J., Li, D., Wilson, W. R., Dachs, G. U., & Patterson, A. V. (2011) · Molecular Pharmacology · doi:10.1124/mol.111.073759 · Cited by 69
Gu, Y., Patterson, A. V., Atwell, G. J., Chernikova, S. B., Brown, J. M., Thompson, L. H., & Wilson, W. R. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-1209 · Cited by 69
Keynote address: Bioreductive mechanisms
Workman, P. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90493-2 · Cited by 68
Gokhale, P., Radhakrishnan, B., Husain, S., Abernethy, D., Sacher, R. A., Dritschilo, A., & Rahman, A. (1996) · British Journal of Cancer · doi:10.1038/bjc.1996.313 · Cited by 68
Cázares-Körner, C., Pires, I. M., Swallow, I. D., Grayer, S. C., O’Connor, L. J., Olcina, M. M., Christlieb, M., Conway, S. J., & Hammond, E. M. (2013) · ACS Chemical Biology · doi:10.1021/cb4001537 · Cited by 68
Goto, H., Izawa, I., Li, P., & Inagaki, M. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02280.x · Cited by 68
Hay, M. P., Pruijn, F. B., Gamage, S. A., Liyanage, H. D. S., Kovacs, M. S., Patterson, A. V., Wilson, W. R., Brown, J. M., & Denny, W. A. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm030399c · Cited by 67
HYPOXIC CELL SENSITISERS IN RADIOTHERAPY
ADAMS, G. E., Fowler, J. F., Dische, S., & Thomlinson, R. H. (1976) · The Lancet · doi:10.1016/s0140-6736(76)91285-x · Cited by 66
INDQ/NO, a Bioreductively Activated Nitric Oxide Prodrug
Sharma, K., Iyer-Bierhoff, A., Sengupta, K., & Chakrapani, H. (2013) · Organic Letters · doi:10.1021/ol400884v · Cited by 64
Synthesis of novel paclitaxel prodrugs designed for bioreductive activation in hypoxic tumour tissue
Damen, E. W. P., Nevalainen, T., van den Bergh, T. J. M., de Groot, F. M. H., & Scheeren, H. W. (2002) · Bioorganic & Medicinal Chemistry · doi:10.1016/s0968-0896(01)00235-8 · Cited by 64
Reduction of Cytotoxic Azo Compounds by Hydrazine and by the Xanthine Oxidase–Xanthine System
Ross, W. C. J., & Warwick, G. P. (1955) · Nature · doi:10.1038/176298a0 · Cited by 64
Tirapazamine with cisplatin in patients with advanced non-small-cell lung cancer: a phase II study.
Treat, J., Johnson, E., Langer, C. J., Belani, C. P., Haynes, B., Greenberg, R., Rodriquez, R., Drobins, P., Miller, W. T., Meehan, L., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.11.3524 · Cited by 64
Thomson, D. J., Yang, H., Baines, H., Miles, E. A., Bolton, S., West, C., & Slevin, N. J. (2014) · Clinical Oncology · doi:10.1016/j.clon.2014.03.003 · Cited by 64
A novel anticancer theranostic pro-prodrug based on hypoxia and photo sequential control
Feng, W., Gao, C., Liu, W., Ren, H., Wang, C., Ge, K., Li, S., Zhou, G., Li, H., Wang, S., et al. (2016) · Chemical Communications · doi:10.1039/c6cc02932a · Cited by 64
Manesh, D. M., El‐Hoss, J., Evans, K., Richmond, J., Toscan, C. E., Bracken, L. S., Hedrick, A., Sutton, R., Marshall, G. M., Wilson, W. R., et al. (2015) · Blood · doi:10.1182/blood-2014-12-618900 · Cited by 63
Huang, B., Desai, A. M., Tang, S., Thomas, T. P., & Baker, J. R. (2010) · Organic Letters · doi:10.1021/ol1002626 · Cited by 63
Tercel, M., Lee, A. E., Hogg, A., Anderson, R. F., Lee, H. H., Siim, B. G., Denny, W. A., & Wilson, W. R. (2001) · Journal of Medicinal Chemistry · doi:10.1021/jm010202l · Cited by 63
Keyes, S. R., Rockwell, S., & Sartorelli, A. C. (1985) · PubMed · Cited by 63
Molecular Imaging of the Tumor Microenvironment for Precision Medicine and Theranostics
Penet, M., Krishnamachary, B., Chen, Z., Jin, J., & Bhujwalla, Z. M. (2014) · Advances in cancer research · doi:10.1016/b978-0-12-411638-2.00007-0 · Cited by 63
Regression of Lung Cancer by Hypoxia-Sensitizing Ruthenium Polypyridyl Complexes
Yadav, A. K., Janaratne, T. K., Krishnan, A., et al. (2013) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-12-1130 · Cited by 62
Le, Q., Moon, J., Redman, M. W., Williamson, S. K., Lara, P. N., Goldberg, Z., Gaspar, L. E., Crowley, J. J., Moore, D. F., & Gandara, D. R. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.3868 · Cited by 62
Translational Medicine and the Value of Biomarker Qualification
Goodsaid, F. M., & Mendrick, D. L. (2010) · Science Translational Medicine · doi:10.1126/scitranslmed.3001040 · Cited by 62
Saggar, J. K., & Tannock, I. F. (2013) · International Journal of Cancer · doi:10.1002/ijc.28595 · Cited by 61
Preferential DNA Cleavage under Anaerobic Conditions by a DNA-Binding Ruthenium Dimer
Janaratne, T. K., Yadav, A. K., Ongeri, F., & MacDonnell, F. M. (2007) · Inorganic Chemistry · doi:10.1021/ic0619714 · Cited by 61
Coleman, C. N., Wasserman, T. H., Urtasun, R. C., et al. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90236-1 · Cited by 61
Hypoxia-Dependent Retinal Toxicity of Bioreductive Anticancer Prodrugs in Mice
Lee, A. E., & Wilson, W. R. (2000) · Toxicology and Applied Pharmacology · doi:10.1006/taap.1999.8834 · Cited by 60
Phillips, R. M., Naylor, M. A., Jaffar, M., Doughty, S. W., Everett, S. A., Breen, A. G., Choudry, G. A., & Stratford, I. J. (1999) · Journal of Medicinal Chemistry · doi:10.1021/jm991063z · Cited by 59
Papadopoulos, K. P., Goel, S., Beeram, M., Wong, A., Desai, K. K., Haigentz, M., Milián, M. L., Mani, S., Tolcher, A. W., Lalani, A. S., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0483 · Cited by 59
Solano, B., Junnotula, V., Marín, A., Villar, R., Burguete, A., Vicente, E. F., Pérez‐Silanes, S., Aldana, I., Monge, A., Dutta, S., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm0703993 · Cited by 57
Shinde, S. S., Hay, M. P., Patterson, A. V., Denny, W. A., & Anderson, R. F. (2009) · Journal of the American Chemical Society · doi:10.1021/ja906860a · Cited by 57
A chemical perspective on the anthracycline antitumor antibiotics.
Abdella, B. R. J., & Fisher, J. F. (1985) · Environmental Health Perspectives · doi:10.1289/ehp.85644 · Cited by 56
Grigsby, P. W., Winter, K. A., Wasserman, T. H., Marcial, V. A., Rotman, M. Z., Cooper, J. S., Keys, H. M., Asbell, S. O., & Phillips, T. L. (1999) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(99)00054-1 · Cited by 56
Seow, H. A., Penketh, P. G., Shyam, K., Rockwell, S., & Sartorelli, A. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409013102 · Cited by 56
Evaluation of bioreductive drugs in multicell spheroids
Durand, R. E., & Olive, P. L. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90504-b · Cited by 55
Plumb, J. A., Gerritsen, M., Milroy, R., Thomson, P., & Workman, P. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90278-x · Cited by 55
Cobalt complexes with tripodal ligands: implications for the design of drug chaperones
Bonnitcha, P., Kim, B. J., Hocking, R. K., Clegg, J. K., TURNER, P. R., Neville, S. M., & Hambley, T. W. (2012) · Dalton Transactions · doi:10.1039/c2dt30727h · Cited by 55
Recent developments in the design of bioreductive drugs.
Denny, W. A., Wilson, W. R., & Hay, M. P. (1996) · Europe PMC (PubMed Central) · Cited by 54
Depenbrock, H., Schmelcher, S., Peter, R., Keppler, B. K., Weirich, G., Block, T. R., Rastetter, J., & Hanauske, A.-R. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00277-3 · Cited by 54
Synthesis and evaluation of prodrugs for anti-angiogenic pyrrolylmethylidenyl oxindoles
Maskell, L., Blanche, E. A., Colucci, M. A., Whatmore, J. L., & Moody, C. J. (2007) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.12.108 · Cited by 54
Kim, H. S., Sharma, A. K., Ren, W. X., Han, J., & Kim, J. S. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.09.006 · Cited by 54
Self-citationSingleton, D. C., Li, D., Bai, S. Y., Syddall, S. P., Smaill, J. B., Shen, Y., Denny, W. A., Wilson, W. R., & Patterson, A. V. (2007) · Cancer Gene Therapy · doi:10.1038/sj.cgt.7701088 · Cited by 51
Zhang, Z., Tanabe, K., Hatta, H., & Nishimoto, S. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b502813b · Cited by 51
Schreiber‐Brynzak, E., Pichler, V., Heffeter, P., Hanson, B. T., Theiner, S., Lichtscheidl, I., Kornauth, C., Bamonti, L., Dhery, V., Groza, D., et al. (2016) · Metallomics · doi:10.1039/c5mt00312a · Cited by 51
Naylor, M. A., Jaffar, M., Nolan, J., Stephens, M. A., Butler, S., Patel, K. B., Everett, S. A., ADAMS, G. E., & Stratford, I. J. (1997) · Journal of Medicinal Chemistry · doi:10.1021/jm9608422 · Cited by 50
Tercel, M., Atwell, G. J., Yang, S., Stevenson, R. J., Botting, K. J., Boyd, M., Smith, E., Anderson, R. F., Denny, W. A., Wilson, W. R., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm901202b · Cited by 49
Ware, D. C., Palmer, H. R., Brothers, P. J., Rickard, C. E. F., Wilson, W. R., & Denny, W. A. (1997) · Journal of Inorganic Biochemistry · doi:10.1016/s0162-0134(97)00090-1 · Cited by 49
Wilson, W. R., Moselen, J. W., Cliffe, S., Denny, W. A., & Ware, D. C. (1994) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(94)90283-6 · Cited by 49
Ikeda, Y., Hisano, H., Nishikawa, Y., & Nagasaki, Y. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00011 · Cited by 49
Xu, S., Yao, H., Pei, L., Hu, M. Y., Li, D., Qiu, Y., Wang, G., Wu, L., Yao, H., Zhu, Z., et al. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.03.055 · Cited by 49
Liu, X.-W., Cai, T.-Y., Zhu, H., Cao, J., Su, Y., Hu, Y.-Z., He, Q.-J., & Yang, B. (2013) · Autophagy · doi:10.4161/auto.26838 · Cited by 48
Volpato, M., Abou-Zeid, N., Tanner, R. W., Glassbrook, L. T., Taylor, J. P., Stratford, I. J., Loadman, P. M., Jaffar, M., & Phillips, R. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0519 · Cited by 48
Li, S., Jiang, X., Zheng, R., Zuo, S., Zhao, L., Fan, G., Fan, J., Liao, Y., Yu, X., & Cheng, H. B. (2018) · Chemical Communications · doi:10.1039/c8cc03430c · Cited by 48
Chang, J. Y.-C., Lu, G., Stevenson, R. J., Brothers, P. J., Clark, G. R., Botting, K. J., Ferry, D. M., Tercel, M., Wilson, W. R., Denny, W. A., et al. (2013) · Inorganic Chemistry · doi:10.1021/ic4006967 · Cited by 46
Hunter, F. W., Hsu, H., Su, J., Pullen, S. M., Wilson, W. R., & Wang, J. (2014) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0476 · Cited by 46
Tercel, M., Atwell, G. J., Yang, S., Ashoorzadeh, A., Stevenson, R. J., Botting, K. J., Gu, Y., Mehta, S. Y., Denny, W. A., Wilson, W. R., et al. (2011) · Angewandte Chemie International Edition · doi:10.1002/anie.201004456 · Cited by 46
Shinde, S. S., Maroz, A., Hay, M. P., Patterson, A. V., Denny, W. A., & Anderson, R. F. (2010) · Journal of the American Chemical Society · doi:10.1021/ja908689f · Cited by 45
Hay, M. P., Pchalek, K., Pruijn, F. B., Hicks, K. O., Siim, B. G., Anderson, R. F., Shinde, S. S., Phillips, V., Denny, W. A., & Wilson, W. R. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm701037w · Cited by 44
Haffty, B. G., Son, Y. H., Wilson, L. D., Papac, R. J., FISCHER, D. B., Rockwell, S., Sartorelli, A. C., Ross, D. A., Sasaki, C. T., & Fischer, J. J. (1997) · Radiation Oncology Investigations · doi:10.1002/(sici)1520-6823(1997)5:5<213::aid-roi1>3.0.co;2-0 · Cited by 44
Hunter, F. W., Wang, J., Patel, R., Hsu, H., Hickey, A. J., Hay, M. P., & Wilson, W. R. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.005 · Cited by 44
Bis-bioreductive agents as hypoxia-selective cytotoxins: Nitracrine N-oxide
Wilson, W. R., van Zijl, P., & Denny, W. A. (1992) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(92)90505-c · Cited by 44
Treatment of head and neck cancer with CHART and nimorazole: phase II study
Henk, J. M., Bishop, K., & Shepherd, S. F. (2003) · Radiotherapy and Oncology · doi:10.1016/s0167-8140(02)00284-0 · Cited by 44
Gammon, L., & Mackenzie, I. C. (2015) · Journal of Oral Pathology and Medicine · doi:10.1111/jop.12327 · Cited by 44
Milbank, J. B. J., Stevenson, R. J., Ware, D. C., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9008746 · Cited by 43
Luo, Y., He, D., Liang, N., Shen, S., Li, L., Li, X., Zhau, H. E., & Chung, L. W. K. (2006) · British Journal of Urology · doi:10.1111/j.1464-410x.2006.06480.x · Cited by 42
Yan, C., Kepa, J. K., Siegel, D. M., Stratford, I. J., & Ross, D. (2008) · Molecular Pharmacology · doi:10.1124/mol.108.050401 · Cited by 42
NLCQ-1 (NSC 709257): exploiting hypoxia with a weak DNA-intercalating bioreductive drug.
Papadopoulou, M. V., & Bloomer, W. D. (2003) · PubMed · Cited by 42
Lv, P.-C., Roy, J., Putt, K. S., & Low, P. S. (2016) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.6b00065 · Cited by 42
Belcourt, M. F., Hodnick, W. F., Rockwell, S., & Sartorelli, A. C. (1998) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(97)00009-5 · Cited by 40
Pavlidis, N. A., Aamdal, S., Awada, A. H., et al. (2000) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s002800000134 · Cited by 40
Marshall, R. S., & Rauth, A. M. (1988) · PubMed · Cited by 40
The radiosensitizing and toxic effects of RSU-1069 on hypoxic cells in a murine tumor
Chaplin, D. J., Durand, R. E., Stratford, I. J., & Jenkins, T. C. (1986) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/0360-3016(86)90233-6 · Cited by 39
Chitneni, S. K., Bida, G. T., Yuan, H., Palmer, G. M., Hay, M. P., Melcher, T., Wilson, W. R., Zalutsky, M. R., & Dewhirst, M. W. (2013) · Journal of Nuclear Medicine · doi:10.2967/jnumed.112.116293 · Cited by 39
Hu, M., Yang, C., Luo, Y., Chen, F., Yang, F., Yang, S., Chen, H., Cheng, Z., Li, K., & Xie, Y. (2018) · Journal of Materials Chemistry B · doi:10.1039/c8tb00546j · Cited by 39
Berardini, M. D., Souhami, R. L., Lee, C. S., Gibson, N. W., Butler, J., & Hartley, J. A. (1993) · Biochemistry · doi:10.1021/bi00064a013 · Cited by 38
Penketh, P. G., Shyam, K., Baumann, R. P., Remack, J. S., Brent, T. P., & Sartorelli, A. C. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-003-0740-7 · Cited by 37
Loadman, P. M., Phillips, R. M., Lim, L. E., & Bibby, M. C. (2000) · Biochemical Pharmacology · doi:10.1016/s0006-2952(99)00391-3 · Cited by 37
Evaluation of the Concept of “Hypoxic Fraction” as a Descriptor of Tumor Oxygenation Status
Evans, S. M., Jenkins, W. T., Shapiro, M. B., & Koch, C. J. (1997) · Advances in experimental medicine and biology · doi:10.1007/978-1-4615-5865-1_26 · Cited by 36
Tercel, M., Lee, H. H., Mehta, S. Y., Youte, J., Bai, S. Y., Liyanage, H. D. S., & Pruijn, F. B. (2017) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.7b00563 · Cited by 36
Dehn, D. L., Winski, S. L., & Ross, D. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0411 · Cited by 35
Phase I pharmacokinetic and pharmacodynamic study of the bioreductive drug RH1
Danson, S. J., Johnson, P., Ward, T. H., Dawson, M. J., Denneny, O., Dickinson, G. L., Aarons, L. J., Watson, A. J., Jowle, D., Cummings, J., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq638 · Cited by 34
Phase II Trial of KW2189 in Patients With Advanced Malignant Melanoma
Markovic, S. N., Suman, V. J., Vukov, A. M., et al. (2002) · American Journal of Clinical Oncology · doi:10.1097/00000421-200206000-00022 · Cited by 34
Retinal Degeneration in Rats Induced by CI-1010, a 2-Nitroimidazole Radiosensitizer
Breider, M. A., Pilcher, G. D., Graziano, M. J., & Gough, A. W. (1998) · Toxicologic Pathology · doi:10.1177/019262339802600207 · Cited by 32
Improved potency of the hypoxic cytotoxin tirapazamine by DNA-targeting
Delahoussaye, Y. M., Hay, M. P., Pruijn, F. B., Denny, W. A., & Brown, J. M. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00199-0 · Cited by 31
Aliphatic amine N-oxides of DNA binding agents as bioreductive drugs.
Patterson, L. H., Craven, M. R., Fisher, G. R., & Teesdale‐Spittle, P. H. (1994) · PubMed · Cited by 31
Johnson, K. M., Parsons, Z. D., Barnes, C. L., & Gates, K. S. (2014) · The Journal of Organic Chemistry · doi:10.1021/jo501252p · Cited by 31
Phillips, R. M., Hendriks, H. R., Sweeney, J. B., Reddy, G., & Peters, G. J. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1341490 · Cited by 30
Characterisation of radicals formed by the triazine 1,4-dioxide hypoxia-activated prodrug, SN30000
Anderson, R. F., Yadav, P., Patel, D. K., Reynisson, J., Tipparaju, S. R., Guise, C. P., Patterson, A. V., Denny, W. A., Maroz, A., Shinde, S. S., et al. (2014) · Organic & Biomolecular Chemistry · doi:10.1039/c4ob00236a · Cited by 29
Nishimura, Y., Nakagawa, K., Takeda, K., Tanaka, M., Segawa, Y., Tsujino, K., Negoro, S., Fuwa, N., Hida, T., Kawahara, M., et al. (2007) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2007.04.008 · Cited by 29
Purkait, K., Karmakar, S., Bhattacharyya, S., Chatterjee, S., Dey, S. K., & Mukherjee, A. (2015) · Dalton Transactions · doi:10.1039/c4dt03983a · Cited by 28
Radiosensitization by Nifuroxime of the Hypoxic Cells in anin VitroTumour Model
Sutherland, R. M., & Durand, R. E. (1972) · International Journal of Radiation Biology and Related Studies in Physics Chemistry and Medicine · doi:10.1080/09553007214551511 · Cited by 28
Bioreductively Activated Lysyl Oxidase Inhibitors against Hypoxic Tumours
Granchi, C., Funaioli, T., Erler, J. T., Giaccia, A. J., Macchia, M., & Minutolo, F. (2009) · ChemMedChem · doi:10.1002/cmdc.200900247 · Cited by 27
The new platinum-based anticancer agent LA-12 induces retinol binding protein 4 in vivo
Bouchal, P., Jarkovský, J., Hrazdilová, K., Dvořáková, M., Struhárová, I., Hernychová, L., Damborský, J., Sova, P., & Vojtěšek, B. (2011) · Proteome Science · doi:10.1186/1477-5956-9-68 · Cited by 27
Bremner, J. C. M. (1993) · Cancer and Metastasis Reviews · doi:10.1007/bf00689809 · Cited by 26
Hunter, F. W., Jaiswal, J. K., Hurley, D., Liyanage, H. D. S., McManaway, S. P., Gu, Y., Richter, S., Wang, J., Tercel, M., Print, C. G., et al. (2014) · Biochemical Pharmacology · doi:10.1016/j.bcp.2014.03.001 · Cited by 26
DT-diaphorase activity in NSCLC and SCLC cell lines: a role for fos/jun regulation
Kepa, J. K., & Ross, D. (1999) · British Journal of Cancer · doi:10.1038/sj.bjc.6690268 · Cited by 26
Electronic structural investigations of ruthenium compounds and anticancer prodrugs
Harris, T. V., Szilagyi, R. K., & Holman, K. L. M. (2009) · JBIC Journal of Biological Inorganic Chemistry · doi:10.1007/s00775-009-0501-0 · Cited by 25
Real Time Dynamic Imaging and Current Targeted Therapies in the War on Cancer: A New Paradigm
Paulmurugan, R., Oronsky, B. T., Brouse, C. F., Reid, T. R., Knox, S. J., & Scicinski, J. J. (2013) · Theranostics · doi:10.7150/thno.5658 · Cited by 24
Reduction of Nitroarylmethyl Quaternary Ammonium Prodrugs of Mechlorethamine by Radiation
Wilson, W. R., Ferry, D. M., Tercel, M., Anderson, R. F., & Denny, W. A. (1998) · Radiation Research · doi:10.2307/3579956 · Cited by 24
Saneyoshi, H., Hiyoshi, Y., Iketani, K., Kondo, K., & Ono, A. M. (2015) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2015.10.025 · Cited by 23
Nakashima, H., Uto, Y., Nakata, E., Nagasawa, H., Ikkyu, K., Hiraoka, N., Nakashima, K., Sasaki, Y., Sugimoto, H., Shiro, Y., et al. (2008) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2008.07.087 · Cited by 23
Novel nitroimidazole alkylsulfonamides as hypoxic cell radiosensitisers
Bonnet, M., Hong, C. R., Gu, Y., Anderson, R. F., Wilson, W. R., Pruijn, F. B., Wang, J., Hicks, K. O., & Hay, M. P. (2014) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2014.02.039 · Cited by 23
Moselen, J. W., Hay, M. P., Denny, W. A., & Wilson, W. R. (1995) · PubMed · Cited by 21
Predictive Biomarkers in the Development of Oncology Drugs: A Therapeutic Industry Perspective
Fine, B. M., & Amler, L. C. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.9 · Cited by 19
Role of NADPH cytochrome P450 reductase in activation of RH1
Begleiter, A., Leith, M. K., Patel, D., & Hasinoff, B. B. (2007) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-007-0417-8 · Cited by 19
Gu, Y., Chang, T. T.-A., Wang, J., Jaiswal, J. K., Edwards, D., Downes, N., Liyanage, H. D. S., Lynch, C. R. H., Pruijn, F. B., Hickey, A. J., et al. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00531 · Cited by 19
Lee, E., George, S., Amrein, P., Paciucci, P. A., Allen, S. L., & Schiffer, C. (1998) · Leukemia · doi:10.1038/sj.leu.2400905 · Cited by 17
NLCQ-1, a novel hypoxic cytotoxin: potentiation of melphalan, cisDDP and cyclophosphamide in vivo
Papadopoulou, M. V., Ji, M., & Bloomer, W. D. (1998) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/s0360-3016(98)00333-2 · Cited by 17
Lavaggi, M. L., Cabrera, M., Pintos, C., Arredondo, C., Pachón, G., Rodríguez, J., Raymondo, S., Pacheco, J. P., Cascante, M., Olea‐Azar, C., et al. (2011) · ISRN Pharmacology · doi:10.5402/2011/314209 · Cited by 16
Papadopoulou, M. V., Ji, M. H., Ji, X., Bloomer, W. D., & Hollingshead, M. G. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0521-8 · Cited by 16
Chang, L., Liu, X., Wang, D., Ma, J., Zhou, T., Chen, Y., Sheng, R., Hu, Y., Du, Y., He, Q., et al. (2015) · PLoS ONE · doi:10.1371/journal.pone.0144506 · Cited by 16
Hasinoff, B. B., Begleiter, A., Hasinoff, B. B., & Begleiter, A. (2006) · Free Radical Research · doi:10.1080/10715760600833077 · Cited by 15
Papadopoulou, M. V., Ji, M., Ji, X., et al. (2002) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-002-0491-x · Cited by 12
Mehibel, M., Singh, S., Cowen, R. L., Williams, K. J., & Stratford, I. J. (2016) · Oncology Reports · doi:10.3892/or.2016.4555 · Cited by 12
El‐Dakdouki, M. H., Adamski, N. L., Foster, L., Hacker, M. P., & Erhardt, P. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm200984x · Cited by 12
Gu, Y., Jaiswal, J. K., Wang, J., Hicks, K. O., Hay, M. P., & Wilson, W. R. (2014) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24099 · Cited by 10
Radiation-chemical Properties of the Hypoxic Cell Radiosensitizer Doranidazole (PR-350)
Kuwabara, M., IIDA, Y., Inanami, O., Sawamura, S., Yokoyama, K., & Tsujitani, M. (2002) · Journal of Radiation Research · doi:10.1269/jrr.43.77 · Cited by 10
Mechanism of Action of AminoCBIs: Highly Reactive but Highly Cytotoxic Analogues of the Duocarmycins
Tercel, M., Pruijn, F. B., O'Connor, P. D., Liyanage, H. D. S., Atwell, G. J., & Alix, S. (2014) · ChemBioChem · doi:10.1002/cbic.201402256 · Cited by 9
Hay, M. P., Denny, W. A., & Wilson, W. R. (1996) · PubMed · Cited by 4
Cited by
Revisiting Fluorescent Calixarenes: From Molecular Sensors to Smart Materials
Kumar, R., Sharma, A., Singh, H., Suating, P., Kim, H. S., Sunwoo, K., Shim, I., Gibb, B. C., & Kim, J. S. (2019) · Chemical Reviews · doi:10.1021/acs.chemrev.8b00605 · Cited by 538
Self-citationMoradi Kashkooli, F., Soltani, M., & Souri, M. (2020) · Journal of Controlled Release · doi:10.1016/j.jconrel.2020.08.012 · Cited by 514
Theranostic Fluorescent Probes
Sharma, A., Verwilst, P., Li, M., Ma, D., Singh, N., Yoo, J., Kim, Y., Yang, Y., Zhu, J.-H., Huang, H., et al. (2024) · Chemical Reviews · doi:10.1021/acs.chemrev.3c00778 · Cited by 499
Self-citationTherapeutic targeting of the hypoxic tumour microenvironment
Singleton, D. C., Macann, A., & Wilson, W. R. (2021) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-021-00539-4 · Cited by 484
Tian, H., Zhang, T., Qin, S., Huang, Z., Zhou, L., Shi, J., Nice, E. C., Xie, N., Huang, C., & Shen, Z. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01320-5 · Cited by 426
Metadata
- Authors
- Sharma, A., Arambula, J. F., Koo, S., Kumar, R., Singh, H., Sessler, J. L., & Kim, J. S.
- Venue
- Chemical Society Reviews
- Publisher
- Royal Society of Chemistry (RSC)
- Published
- 2019
- Volume
- 48
- Issue
- 3
- Pages
- 771-813
- ISSN
- 0306-0012 (ISSN-L)
- 1460-4744
- OpenAlex
- W2906405458
- Cited by
- 542
- References
- 318
- FWCI
- 4.87
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.